Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) ...

Explore the 10 best anti-inflammatory supplements reviewed by RDs. From joint support to heart health, these expert-approved picks are worth trying in 2026.

Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News CommentaryVANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is ...

Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the co ...

A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

█ ...

A research team reports a metal-free catalytic strategy that completely converts waste PET into two high-value ...

If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...

Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across ...